Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online May 7 in the Journal of the American Medical Association.

Amanda K. Rudman Spergel, M.D., from Moderna Inc. in Cambridge, Massachusetts, and colleagues examined the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults aged 50 years and older in a trial conducted across 146 U.S. sites. Adults aged 65 years and older (4,017 participants) and 50 to 64 years (3,998 participants) were randomly assigned to receive mRNA-1083 plus placebo or coadministered licensed quadrivalent seasonal influenza (65 years and older: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50 to 64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (mRNA-1273) vaccines.

The researchers found that based on the lower bound of the 97.5 percent confidence interval of the geometric mean ratio greater than 0.667 and lower bound of the 97.5 percent confidence interval of the seroconversion/seroresponse rate difference greater than −10 percent, noninferior immunogenicity of mRNA-1083 was demonstrated against all vaccine-matched influenza and SARS-CoV-2 strains. Higher immune responses were elicited by mRNA-1083 than SD-IIV4 (50 to 64 years) for all four influenza strains and HD-IIV4 (65 years and older) for three influenza strains, and against SARS-CoV-2 (all ages). Relative to comparators, solicited adverse reactions were numerically higher in frequency and severity after mRNA-1083 vaccination than comparators in both age cohorts.

"This pivotal phase 3 study demonstrated the noninferiority of a single mRNA-1083 dose in adults 50 years and older," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Moderna, which is developing the mRNA-1083 vaccine and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-10 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords